GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ThermoGenesis Holdings Inc (STU:THR) » Definitions » Valuation Rank

ThermoGenesis Holdings (STU:THR) Valuation Rank


View and export this data going back to . Start your Free Trial

What is ThermoGenesis Holdings Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

ThermoGenesis Holdings Valuation Rank Related Terms

Thank you for viewing the detailed overview of ThermoGenesis Holdings's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

ThermoGenesis Holdings (STU:THR) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ThermoGenesis Holdings Inc (STU:THR) » Definitions » Valuation Rank
Comparable Companies
ADMT VAPO NUWE QLIS RSLS BIOL FOMI NUMD VYCO OPGN ABT SYK BSX MDT XTER:SHL EW DXCM SZSE:300760 XAMS:PHIA ZBH
Traded in Other Exchanges
THMO:USA
Address
2711 Citrus Road, Rancho Cordova, CA, USA, 95742
Website
https://www.thermogenesis.com
ThermoGenesis Holdings Inc develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. It offers the AutoXpress and BioArchive platforms for automated clinical bio-banking, PXP platform for point-of-care cell-based therapies and CAR-TXpress platform for bio-manufacturing for immuno-oncology applications.